An investigation of the pharmacokinetics of topical Lamisil® 1% cream

Twenty volunteers were entered into a study to investigate the pharmacokinetics of Lamisil® 1% cream. The subjects were
randomized to receive Lamisil® 1% cream applied to the skin on the back on 1 day, or on 3, 5 or 7 consecutive days.
Up to five biopsies were taken at a site on the upper back at various time-points both during treatment and after
treatment. Lamisil® levels in the biopsies were analyzed using HPLC.
The study showed that increasing the number of applications from one to seven did not significantly increase the peak
concentration (Cmax) in the stratum corneum.
However, there was an increase in the total amount of Lamisil® found in the stratum corneum resulting in Lamisil® being
detected for longer periods after cessation of therapy.
Treatment for 7 days resulted in Lamisil® still being detectable 7 days after cessation of therapy, and the drug
concentration was significantly higher than the concentration killing the common causative organisms of superficial
dermatomycoses.
This study indicates a significant potential for short-term treatment with Lamisil® 1% cream in superficial
dermatomycoses.

pharmacokinetics of Lamisil, short-term treatment